3-37048955-G-C
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PP4PM2_Supporting
This summary comes from the ClinGen Evidence Repository: The NM_000249.4: c.2041G>C variant in MLH1 is a missense variant predicted to cause substitution of Alanin by Prolin at amino acid 681 (p.Ala681Pro). The variant is not reported in gnomAD (PM2_supporting). The variant was detected in one CRC/Endometrial MSI-H tumour using a standard panel of 5-10 markers and/or loss of MMR protein expression consistent with the variant location (PP4). In summary, this variant meets the criteria to be classified as a variant of uncertain significance (VUS) for Lynch-Syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen InSiGHT Hereditary Colorectal Cancer/ Polyposis VCEP: PM2_SUP, PP4 (VCEP specifications version 1) LINK:https://erepo.genome.network/evrepo/ui/classification/CA10578272/MONDO:0007356/115
Frequency
Consequence
NM_000249.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:2
The p.A681P pathogenic mutation (also known as c.2041G>C), located in coding exon 18 of the MLH1 gene, results from a G to C substitution at nucleotide position 2041. The alanine at codon 681 is replaced by proline, an amino acid with highly similar properties. This alteration has been detected in patients diagnosed with early-onset MLH1- or MLH1/ PMS2-deficient colorectal cancers, whose families meet Amsterdam criteria (Ambry internal data). A similar alteration, MLH1 p.A681V, was reported in one family that met Bethesda Criteria from a cohort of 98 probands (Wei W et al. BMB Rep 2011 May; 44(5):317-22). Further, a well-characterized mutation at the same codon, p.A681T (c.2041G>A), has been identified in multiple families either meeting Amsterdam II criteria or whose family history was suggestive of HNPCC/Lynch syndrome and has also been shown to co-segregate with disease (Froggatt et al. J Med Genet. 1996 Sep; 33(9): 762-30; Shimodaira et al. Nat Genet 1998 Aug; 19(4): 384-9; Kurzawski G et al. Clin. Genet. 2006 Jan; 69(1):40-7; Barnetson RA et al. Hum. Mutat. 2008 Mar; 29(3):367-74). Based on internal structural assessment, this alteration locally destabilizes the folding of the MLH1 C-terminal domain (Berman HM et al. Nucleic Acids Res. 2000 Jan;28:235-42 (3RBN unpublished structure)). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
This missense variant replaces alanine with proline at codon 681 of the MLH1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown that this variant has normal mismatch repair in vitro but reduced protein expression/stability, 41-53% of wildtype (PMID: 21404117, 22736432, 23403630). This variant has been reported in multiple individuals affected with Lynch syndrome (PMID: 8880570, 16083711, 16142001, 16341804, 17054581, 17473388, 18033691, 19731080, 20007843, 20305446, 21404117, 21615986, 21642682, 22034109, 22736432). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic. -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Ala681 amino acid residue in MLH1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 2362047, 8880570, 18033691, 21642682, 22736432). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MLH1 protein function. ClinVar contains an entry for this variant (Variation ID: 233523). This missense change has been observed in individual(s) with clinical features of Lynch syndrome (PMID: 21520333; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces alanine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 681 of the MLH1 protein (p.Ala681Pro). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at